Do you want to read an article? Please log in or register.
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
Pulmonary FibrosisFurther Publications
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
Ther Adv Respir Dis
Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, Salvatore D, Terlizzi V
doi: 10.1177/17534666251314706
RECOMMENDED
Pulmonary Fibrosis
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(24)00208-X
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A
doi: 10.1016/S2213-2600(24)00411-9
Pulmonary Fibrosis
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Respir Med
Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V
doi: 10.1016/j.rmed.2025.108221
Pulmonary Fibrosis
Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US
Respir Med
Merlo C, Geiger JM, Wang Z, Lyden GR, Schladt DP, McGarry L
doi: 10.1016/j.rmed.2025.108171
RECOMMENDED
Pulmonary Fibrosis
Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Caley LR, Gillgrass L, Zagoya C, Saumtally H, Duckstein F, H W, Mainz JG, Peckham DG
doi: 10.1016/j.jcf.2025.01.010
RECOMMENDED
Further Publications
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M, VX17-445-105 Study Group
doi: 10.1164/rccm.202411-2231OC
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G
doi: 10.1016/S2213-2600(24)00407-7